AKT as a therapeutic target in multiple myeloma

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 8, 2014, Pages 897-915

  Keane, Niamh A ^a   Glavey, Siobhan V ^a   Krawczyk, Janusz ^a   O'Dwyer, Michael ^a  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Afuresertib; AKT; AKT inhibitor; Alkylphospholipid; Allosteric inhibitor; ATP competitive; MK 2206; Multiple myeloma; Perifosine; Phosphatidylinositol 3 kinase; Pleckstrin homology domain; Triciribine

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFURESERTIB; ALVESPIMYCIN; BORTEZOMIB; CASPASE 9; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN D1; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR 2; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 3; INTERLEUKIN 6; JANUS KINASE 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN MDM2; STAT PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA; SURVIVIN; TEMSIROLIMUS; TRAMETINIB; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UPROSERTIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR;

APOPTOSIS; AUTOPHAGY; BINDING SITE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; UPREGULATION; VIRUS ONCOGENE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG POTENTIATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DESIGN; DRUG SYNERGISM; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84904426792     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.924507     Document Type: Review

References (159)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111(5):2516-20
2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364(11):1046-60
3. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients. Leukemia 2014;28(5):1122-8
4. Usmani SZ, Crowley J, Hoering A, et al. Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: Are patients now being cured Leukemia 2013;27(1):226-32
5. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia 2012;26(1):149-57
6. Staal SP, Hartley JW, Rowe WP. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc Natl Acad Sci USA 1977;74(7):3065-7 (Pubitemid 8132494)
7. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987;84(14):5034-7 (Pubitemid 17095859)
8. Coffer PJ, Woodgett JR. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem 1991;201(2):475-81
9. Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991;254(5029):274-7 (Pubitemid 21917339)
10. Ahmed NN, Franke TF, Bellacosa A, et al. The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential. Oncogene 1993;8(7):1957-63 (Pubitemid 23212429)
11. Murthy SS, Tosolini A, Taguchi T, Testa JR. Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization. Cytogenet Cell Genet 2000;88(1-2):38-40 (Pubitemid 30175592)
12. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005;9(1):59-71
13. James SR, Downes CP, Gigg R, et al. Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3, 4, 5-trisphosphate without subsequent activation. Biochem J 1996;315(Pt 3):709-13 (Pubitemid 26147592)
14. Frech M, Andjelkovic M, Ingley E, et al. High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity. J Biol Chem 1997;272(13):8474-81 (Pubitemid 27147810)
15. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7(8):606-19 (Pubitemid 44100518)
16. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005;5(12):921-9 (Pubitemid 41766781)
17. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2(7):489-501 (Pubitemid 37328931)
18. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: The PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006;6(3):184-92 (Pubitemid 43292562)
19. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999;96(8):4240-5 (Pubitemid 29190320)
20. Alessi DR, Deak M, Casamayor A, et al. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): Structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 1997;7(10):776-89 (Pubitemid 27441832)
21. Stephens L, Anderson K, Stokoe D, et al. Protein kinase B kinases that mediate phosphatidylinositol 3, 4, 5-trisphosphatedependent activation of protein kinase B. Science 1998;279(5351):710-14 (Pubitemid 28144551)
22. Kennedy SG, Kandel ES, Cross TK, Hay N. Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 1999;19(8):5800-10 (Pubitemid 29339934)
23. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96(6):857-68 (Pubitemid 29165088)
24. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulinlike growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997;17(3):1595-606 (Pubitemid 27097389)
25. Del Peso L, Gonzalez-Garcia M, Page C, et al. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997;278(5338):687-9 (Pubitemid 27464966)
26. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428(6980):332-7 (Pubitemid 38418805)
27. Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002;21(43):6587-97. (Pubitemid 35177037)
28. Sancak Y, Thoreen CC, Peterson TR, et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 2007;25(6):903-15 (Pubitemid 46436534)
29. Long X, Ortiz-Vega S, Lin Y, Avruch J. Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J Biol Chem 2005;280(25):23433-6 (Pubitemid 40884818)
30. Shi Y, Yan H, Frost P, et al. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/ phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005;4(10):1533-40 (Pubitemid 41556435)
31. Martelli AM, Nyakern M, Tabellini G, et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006;20(6):911-28 (Pubitemid 43797279)
32. Hemmings BA. Akt signaling: Linking membrane events to life and death decisions. Science 1997;275(5300):628-30 (Pubitemid 27061321)
33. Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and upregulation of intracellular antiapoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications. Oncogene 2002;21(37):5673-83. (Pubitemid 35333000)
34. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001;20(42):5991-6000. (Pubitemid 32955041)
35. Tazzari PL, Cappellini A, Ricci F, et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 2007;21(3):427-38
36. Hsu J, Shi Y, Krajewski S, et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001;98(9):2853-5.
37. Hsu JH, Shi Y, Hu L, et al. Role of the AKT kinase in expansion of multiple myeloma clones: Effects on cytokinedependent proliferative and survival responses. Oncogene 2002;21(9):1391-400. (Pubitemid 34214504)
38. Zollinger A, Stuhmer T, Chatterjee M, et al. Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood 2008;112(8):3403-11.
39. Ge NL, Rudikoff S. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo. Oncogene 2000;19(36):4091-5
40. Hyun T, Yam A, Pece S, et al. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood 2000;96(10):3560-8.
41. Choi Y, Zhang J, Murga C, et al. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene 2002;21(34):5289-300 (Pubitemid 34948140)
42. Zhang J, Choi Y, Mavromatis B, et al. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway. Oncogene 2003;22(40):6289-95 (Pubitemid 37281658)
43. Ismail SI, Mahmoud IS, Msallam MM, Sughayer MA. Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma. Leuk Res 2010;34(6):824-6.
44. Chang H, Qi XY, Claudio J, et al. Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res 2006;30(3):262-5 (Pubitemid 43053219)
45. Steinbrunn T, Stuhmer T, Gattenlohner S, et al. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood 2011;117(6):1998-2004.
46. Shi Y, Hsu JH, Hu L, et al. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. J Biol Chem 2002;277(18):15712-20 (Pubitemid 34967845)
47. Hu L, Shi Y, Hsu JH, et al. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003;101(8):3126-35 (Pubitemid 36858006)
48. Klein B, Tarte K, Jourdan M, et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 2003;78(2):106-13 (Pubitemid 37021949)
49. Podar K, Tai YT, Cole CE, et al. Essential role of caveolae in interleukin-6-and insulin-like growth factor Itriggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem 2003;278(8):5794-801 (Pubitemid 36800825)
50. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000;96(8):2856-61
51. Descamps G, Pellat-Deceunynck C, Szpak Y, et al. The magnitude of Akt/phosphatidylinositol 3'-kinase proliferating signaling is related to CD45 expression in human myeloma cells. J Immunol 2004;173(8):4953-9 (Pubitemid 39387777)
52. Chiron D, Maiga S, Surget S, et al. Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells. Blood Cancer J 2013;3:e120
53. Hsu JH, Shi Y, Frost P, et al. Interleukin-6 activates phosphoinositol-3' kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways. Oncogene 2004;23(19):3368-75 (Pubitemid 38669826)
54. Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: Roles in cytokine-dependent survival and proliferative responses. Cancer Res 2000;60(23):6763-70
55. G-Amlak M, Uddin S, Mahmud D, et al. Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. Biochem Biophys Res Commun 2002;297(4):760-4 (Pubitemid 35230315)
56. Abroun S, Ishikawa H, Tsuyama N, et al. Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha [corrected]. Blood 2004;103(6):2291-8 (Pubitemid 38326249)
57. Lentzsch S, Chatterjee M, Gries M, et al. PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 2004;18(11):1883-90 (Pubitemid 39530020)
58. Hideshima T, Chauhan D, Hayashi T, et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther 2002;1(7):539-44
59. Podar K, Catley LP, Tai YT, et al. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood 2004;103(9):3474-9 (Pubitemid 38525680)
60. Tsubaki M, Kato C, Manno M, et al. Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways. Mol Cell Biochem 2007;304(1-2):53-60 (Pubitemid 47456852)
61. Lentzsch S, Gries M, Janz M, et al. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003;101(9):3568-73 (Pubitemid 36857943)
62. Tai YT, Podar K, Mitsiades N, et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood 2003;101(7):2762-9 (Pubitemid 36857641)
63. Qiang YW, Yao L, Tosato G, Rudikoff S. Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. Blood 2004;103(1):301-8 (Pubitemid 38029952)
64. Tai YT, Podar K, Catley L, et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res 2003;63(18):5850-8 (Pubitemid 37187484)
65. Coluccia AM, Cirulli T, Neri P, et al. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: Preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 2008;112(4):1346-56
66. Hecht M, Von Metzler I, Sack K, et al. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). Exp Cell Res 2008;314(5):1082-93 (Pubitemid 351273201)
67. Cao H, Zhu K, Qiu L, et al. Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis. J Biol Chem 2013;288(42):30399-410
68. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004;103(8):3148-57 (Pubitemid 38451693)
69. Zhang HR, Chen JM, Zeng ZY, Que WZ. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity. J Int Med Res 2013;41(3):584-95
70. Lee SW, Cho HY, Na G, et al. CD40 stimulation induces vincristine resistance via AKT activation and MRP1 expression in a human multiple myeloma cell line. Immunol Lett 2012;144(1-2):41-8
71. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005;55(3):178-94 (Pubitemid 40826487)
72. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004;15(2):177-82 (Pubitemid 38251646)
73. Younes H, Leleu X, Hatjiharissi E, et al. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res 2007;13(13):3771-5 (Pubitemid 47037580)
74. Lai KM, Gonzalez M, Poueymirou WT, et al. Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol Cell Biol 2004;24(21):9295-304 (Pubitemid 39391668)
75. Yang ZZ, Tschopp O, Baudry A, et al. Physiological functions of protein kinase B/Akt. Biochem Soc Trans 2004;32(Pt 2):350-4 (Pubitemid 38582126)
76. Lindhurst MJ, Sapp JC, Teer JK, et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 2011;365(7):611-19
77. Yang ZZ, Tschopp O, Hemmings-Mieszczak M, et al. Protein kinase B alpha/Akt1 regulates placental development and fetal growth. J Biol Chem 2003;278(34):32124-31 (Pubitemid 37048402)
78. Plaks V, Berkovitz E, Vandoorne K, et al. Survival and size are differentially regulated by placental and fetal PKBalpha/AKT1 in mice. Biol Reprod 2011;84(3):537-45
79. Cho H, Mu J, Kim JK, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001;292(5522):1728-31 (Pubitemid 32506248)
80. Easton RM, Cho H, Roovers K, et al. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 2005;25(5):1869-78 (Pubitemid 40280150)
81. Tschopp O, Yang ZZ, Brodbeck D, et al. Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development 2005;132(13):2943-54 (Pubitemid 41086730)
82. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24(50):7455-64 (Pubitemid 41637985)
83. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448(7152):439-44 (Pubitemid 47123510)
84. Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4(12):988-1004
85. Cheung M, Testa JR. Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets 2013;13(3):234-44
86. Lindsley CW, Zhao Z, Leister WH, et al. Allosteric Akt (PKB) inhibitors: Discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett 2005;15(3):761-4 (Pubitemid 40143162)
87. Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004;166(2):213-23 (Pubitemid 38988774)
88. Hresko RC, Mueckler M. mTOR. RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 2005;280(49):40406-16 (Pubitemid 41780527)
89. Vasudevan KM, Barbie DA, Davies MA, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009;16(1):21-32
90. Meuillet EJ, Zuohe S, Lemos R, et al. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther 2010;9(3):706-17
91. She QB, Chandarlapaty S, Ye Q, et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008;3(8):e3065
92. Alessi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 1998;8(1):55-62 (Pubitemid 28122141)
93. Yang J, Cron P, Thompson V, et al. Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell 2002;9(6):1227-40 (Pubitemid 34722302)
94. Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-Akt): A multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 1998;335(Pt 1):1-13 (Pubitemid 28477043)
95. Lin K, Lin J, Wu WI, et al. An ATP-site on-off switch that restricts phosphatase accessibility of Akt. Sci Signal 2012;5(223):ra37
96. Han EK, Leverson JD, Mcgonigal T, et al. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 2007;26(38):5655-61 (Pubitemid 47267835)
97. Okuzumi T, Fiedler D, Zhang C, et al. Inhibitor hijacking of Akt activation. Nat Chem Biol 2009;5(7):484-93.
98. Rhodes N, Heerding DA, Duckett DR, et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 2008;68(7):2366-74 (Pubitemid 351521811)
99. Cherrin C, Haskell K, Howell B, et al. An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biol Ther 2010;9(7):493-503
100. Wu WI, Voegtli WC, Sturgis HL, et al. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLoS One 2010;5(9):e12913.
101. Barnett SF, Defeo-Jones D, Fu S, et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 2005;385(Pt 2):399-408 (Pubitemid 40165072)
102. Calleja V, Laguerre M, Parker PJ, Larijani B. Role of a novel PH-kinase domain interface in PKB/Akt regulation: Structural mechanism for allosteric inhibition. PLoS Biol 2009;7(1):e17
103. O'reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66(3):1500-8 (Pubitemid 43259931)
104. Green CJ, Goransson O, Kular GS, et al. Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake. J Biol Chem 2008;283(41):27653-67
105. Ramakrishnan V, Kimlinger T, Haug J, et al. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. PLoS One 2012;7(11):e50005.
106. Workman P, Clarke PA, Guillard S, Raynaud FI. Drugging the PI3 kinome. Nat Biotechnol 2006;24(7):794-6 (Pubitemid 44086618)
107. Rebecchi MJ, Scarlata S. Pleckstrin homology domains: A common fold with diverse functions. Annu Rev Biophys Biomol Struct 1998;27:503-28 (Pubitemid 28286023)
108. Huang BX, Kim HY. Probing Aktinhibitor interaction by chemical crosslinking and mass spectrometry. J Am Soc Mass Spectrom 2009;20(8):1504-13
109. Berndt N, Yang H, Trinczek B, et al. The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. Cell Death Differ 2010;17(11):1795-804.
110. Schweinsberg PD, Smith RG, Loo TL. Identification of the metabolites of an antitumor tricyclic nucleoside (NSC-154020). Biochem Pharmacol 1981;30(18):2521-6 (Pubitemid 11042498)
111. Kondapaka SB, Singh SS, Dasmahapatra GP, et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2(11):1093-103
112. Gills JJ, Dennis PA. Perifosine: Update on a novel Akt inhibitor. Curr Oncol Rep 2009;11(2):102-10
113. Van Blitterswijk WJ, Verheij M. Anticancer alkylphospholipids: Mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des 2008;14(21):2061-74
114. Bellacosa A, Chan TO, Ahmed NN, et al. Akt activation by growth factors is a multiple-step process: The role of the PH domain. Oncogene 1998;17(3):313-25 (Pubitemid 28383008)
115. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006;107(10):4053-62 (Pubitemid 43726814)
116. Levy DS, Kahana JA, Kumar R. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood 2009;113(8):1723-9
117. Spencer A, Yoon S-S, Harrison SJ, et al. Novel AKT inhibitor GSK2110183 shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Preliminary results from a phase I first-time-in-human study. ASH Annual Meeting Abstracts 2011;118(21):1856.
118. Spencer A, Sutherland HJ, O'dwyer ME, et al. Novel AKT inhibitor afuresertib in combination with bortezomib and dexamethasone demonstrates favorable safety profile and significant clinical activity in patients with relapsed/refractory multiple myeloma. Blood 2013;122(21):283
119. Balasis ME, Forinash KD, Chen YA, et al. Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clin Cancer Res 2011;17(9):2852-62
120. Richardson PG, Wolf J, Jakubowiak A, et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: Results of a multicenter phase I/II trial. J Clin Oncol 2011;29(32):4243-9
121. Richardson P, Wolf JL, Jakubowiak A, et al. Perifosine in combination with bortezomib and dexamethasone extends progression-free survival and overall survival in relapsed/refractory multiple myeloma patients previously treated with bortezombib: Updated phase I/II trial results. ASH Annual Meeting Abstracts 2009;114(22):1869
122. Nagler A, Ben-Yehuda D, Badros A, et al. Randomized placebo-controlled phase III study of perifosine combined with bortezomib and dexamethasone in relapsed, refractory multiple myeloma patients previously treated with bortezomib. Blood 2013;122(21):3189
123. Frost P, Moatamed F, Hoang B, et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004;104(13):4181-7 (Pubitemid 39620172)
124. Frost P, Shi Y, Hoang B, Lichtenstein A. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 2007;26(16):2255-62 (Pubitemid 46572812)
125. Cirstea D, Hideshima T, Rodig S, et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 2010;9(4):963-75
126. Stengel C, Cheung CW, Quinn J, et al. Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype. Leukemia 2012;26(8):1761-70
127. Baumann P, Schneider L, Mandl-Weber S, et al. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs 2012;23(1):131-8
128. Chng WJ, Gonzalez-Paz N, Price-Troska T, et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 2008;22(12):2280-4
129. Liu P, Leong T, Quam L, et al. Activating mutations of N-and K-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 1996;88(7):2699-706 (Pubitemid 26327523)
130. Rowley M, Liu P, Van Ness B. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. Blood 2000;96(9):3175-80.
131. Steinbrunn T, Stuhmer T, Sayehli C, et al. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma. Br J Haematol 2012;159(4):430-40
132. Alsina M, Fonseca R, Wilson EF, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004;103(9):3271-7 (Pubitemid 38525650)
133. Hensley LE, Geisbert TW. The contribution of the endothelium to the development of coagulation disorders that characterize Ebola hemorrhagic fever in primates. Thromb Haemost 2005;94(2):254-61 (Pubitemid 41122478)
134. Pei XY, Dai Y, Rahmani M, et al. The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells. Clin Cancer Res 2005;11(12):4589-600 (Pubitemid 40825650)
135. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999;286(5445):1741-4 (Pubitemid 129515882)
136. Hoeflich KP, O'brien C, Boyd Z, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009;15(14):4649-64
137. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118(9):3065-74
138. Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011;17(5):989-1000
139. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009;23(1):10-24
140. Ramakrishnan V, Kimlinger T, Haug J, et al. TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. Am J Hematol 2010;85(9):675-86
141. Mitsiades CS, Mitsiades NS, Mcmullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006;107(3):1092-100 (Pubitemid 43156310)
142. Richardson PG, Mitsiades CS, Laubach JP, et al. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol 2011;152(4):367-79
143. Duus J, Bahar HI, Venkataraman G, et al. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leuk Lymphoma 2006;47(7):1369-78 (Pubitemid 44269648)
144. Lamottke B, Kaiser M, Mieth M, et al. The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. Eur J Haematol 2012;88(5):406-15
145. Khong T, Spencer A. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol Cancer Ther 2011;10(10):1909-17
146. Huston A, Leleu X, Jia X, et al. Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res 2008;14(3):865-74 (Pubitemid 351231171)
147. Podar K, Raab MS, Chauhan D, Anderson KC. The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs 2007;16(10):1693-707 (Pubitemid 350030716)
148. Neri A, Marmiroli S, Tassone P, et al. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma 2008;49(7):1374-83 (Pubitemid 352015802)
149. Bahlis NJ, Miao Y, Koc ON, et al. N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells. Leuk Lymphoma 2005;46(6):899-908 (Pubitemid 40959679)
150. Baumann P, Armann J, Mandl-Weber S, et al. Inhibitors of protein kinase C sensitise multiple myeloma cells to common genotoxic drugs. Eur J Haematol 2008;80(1):37-45 (Pubitemid 350265228)
151. Jourdan E, Leblond V, Maisonneuve H, et al. A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma. Leuk Lymphoma 2014. [Epub ahead of print]
152. Mitsiades CS, Mitsiades NS, Mcmullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5(3):221-30 (Pubitemid 38402114)
153. Bertrand FE, Steelman LS, Chappell WH, et al. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia 2006;20(7):1254-60 (Pubitemid 43905829)
154. Descamps G, Wuilleme-Toumi S, Trichet V, et al. CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642. J Immunol 2006;177(6):4218-23 (Pubitemid 44359958)
155. Swords R, Kelly K, Carew J, et al. The Pim kinases: New targets for drug development. Curr Drug Targets 2011;12(14):2059-66
156. Asano J, Nakano A, Oda A, et al. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia 2011;25(7):1182-8
157. Lu J, Zavorotinskaya T, Dai Y, et al. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood 2013;122(9):1610-20
158. Langowski JL, Holash J, Burger M, et al. The pan-PIM kinase inhibitor LGH447 shows activity in PIM2-dependent multiple myeloma and in AML models. Blood 2013;122(21):1666
159. Ocio EM, Thomas SK, Günther A, et al. Phase 1 study of the novel pan-pim kinase inhibitor LGH447 in patients with relapsed/refractory multiple myeloma. Blood 2013;122(21):3186